시장보고서
상품코드
1825551

세계의 성감염증(STI) 시장 보고서(2025년)

Sexually Transmitted Infections (STIs) Global Market Report 2025

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

성감염증(STI) 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 연평균 성장률(CAGR) 12.0%로 1,120억 2,000만 달러로 성장합니다. 예측 기간의 성장은 새로운 STI 균주, 백신 접종 노력, 원격의료 및 재택 검사,성 건강의 형평성에 기인합니다. 예측 기간의 주요 동향으로는 항균제 내성 증가, 노출 전 예방(pre-exposure prophylaxis), STI 자가 관리, 성교육 강화 등이 있습니다.

향후 5년간 12.0%의 성장률 전망은 지난번 전망치보다 0.1% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 장벽은 벨기에와 중국에서 조달하는 다중중합효소연쇄반응성감염증 패널과 매독 신속검사 비용을 상승시키고, 진단을 지연시키며, 공중보건 검진 프로그램 비용을 상승시킴으로써 미국을 억제할 것으로 예측됩니다. 또한 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

정부 주도의 구상은 성병(STI) 시장의 성장을 가속하는 데 매우 중요한 역할을 하고 있습니다. 이러한 정부의 구상은 STI에 대한 인식을 높이기 위한 다양한 프로그램과 정책을 포함하고 있으며, 시장 확대의 원동력이 될 것으로 기대되고 있습니다. 이러한 프로그램은 STI와 관련된 문제를 해결하기 위해 특별히 고안되었으며, 일반적으로 STI에 대한 인지도를 높이기 위한 공공 교육 캠페인에 자금을 할당하는 것을 포함합니다. 또한 정부의 구상에는 특정 STI를 예방할 수 있는 백신 개발, 무료 또는 저비용 검진 및 검사 서비스 제공 등이 포함될 수 있습니다. 주목할 만한 사례로, 2023년 4월 스프링필드-그린 카운티 보건소가 미주리 주 보건 노인 서비스국(Missouri Department of Health and Senior Services, Missouri DHSS)과 공동으로 시작한 질병 중재 전문가(Disease Intervention Specialist, DIS) 프로그램을 들 수 있습니다. Disease Intervention Specialist, DIS) 프로그램이 있습니다. 이 프로그램은 매독과 HIV를 중심으로 증가하는 성병에 대한 대책에 중점을 두고 있습니다. DIS 프로그램에서는 이러한 감염에 양성으로 판정된 사람에게 전문가가 적극적으로 접근하여 치료 접근을 촉진하고, 감염 가능성에 대한 인식을 높이기 위해 접촉자 추적을 보장합니다. 따라서 정부 구상은 성병(STI) 시장의 성장을 가속하는 요인이 될 것으로 예측됩니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

  • 세계의 성감염증(STI) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
  • 최종 용도 산업의 분석
  • 세계의 성감염증(STI) 시장 : 성장률 분석
  • 세계의 성감염증(STI) 시장 실적 : 규모와 성장, 2019-2024
  • 세계의 성감염증(STI) 시장 예측 : 규모와 성장, 2024-2029, 2034F
  • 세계의 성감염증(STI) : TAM(Total Addressable Market)

제6장 시장 세분화

  • 세계의 성감염증(STI) 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 인간면역결핍바이러스(HIV)
  • 인유두종바이러스(HPV)
  • 임질
  • 매독
  • 기타 유형
  • 세계의 성감염증(STI) 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 항생제
  • 항바이러스제
  • 세계의 성감염증(STI) 시장 : 검사장소별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 임상 검사
  • POC(Point-Of-Care) 검사
  • 세계의 성감염증(STI) 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 경구
  • 비경구
  • 기타 투여 경로
  • 세계의 성감염증(STI) 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 병원
  • 전문 클리닉
  • 홈케어
  • 기타 최종사용자
  • 세계의 성감염증(STI) 시장 : 서브 세분화 인간면역결핍바이러스(HIV)(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • HIV 유형 1
  • HIV 유형 2
  • 세계의 성감염증(STI) 시장 : 서브 세분화 인유두종바이러스(HPV)(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 저위험 HPV
  • 고리스크 HPV
  • 세계의 성감염증(STI) 시장 : 서브 세분화 임질(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 단순 임질
  • 복잡성 임질
  • 세계의 성감염증(STI) 시장 : 서브 세분화 매독(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 1차 매독
  • 2차 매독
  • 3차 매독
  • 세계의 성감염증(STI) 시장 : 서브 세분화 기타 유형(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 클라미디아
  • 단순 헤르페스 바이러스(HSV)
  • B형 간염
  • C형 간염
  • 트리코모나스증

제7장 지역별·국가별 분석

  • 세계의 성감염증(STI) 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 세계의 성감염증(STI) 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

  • 성감염증(STI) 시장 : 경쟁 구도
  • 성감염증(STI) 시장 : 기업 개요
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • Roche Holdings AG Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
    • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 대기업과 혁신적 기업

  • Novartis AG
  • Sanofi SA
  • Bristol-Myers Squibb
  • Astra Zeneca Pharmaceuticals LP
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Gilead Sciences Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Astellas Pharma Inc.
  • Daiichi Sankyo Co. Ltd.
  • Hetero Drugs Ltd.
  • Eisai Co. Ltd.
  • Boehringer Ingelheim Group
  • Sun Pharmaceutical Industries Ltd.

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

  • 성감염증(STI) 시장 2029 : 새로운 기회를 제공하는 국가
  • 성감염증(STI) 시장 2029 : 새로운 기회를 제공하는 부문
  • 성감염증(STI) 시장 2029 : 성장 전략
    • 시장 동향에 기반한 전략
    • 경쟁사 전략

제36장 부록

KSA 25.10.15

Sexually transmitted infections (STIs), also referred to as sexually transmitted diseases (STDs), are a group of illnesses caused by viruses, bacteria, and parasites that are transmitted from one individual to another through sexual contact. These infections can be spread through vaginal, anal, and oral sexual intercourse, as well as through skin-to-skin contact.

The primary types of sexually transmitted infections (STIs) include human immunodeficiency virus (HIV), human papillomavirus (HPV), gonorrhea, syphilis, and others. Human Immunodeficiency Virus (HIV) is a virus that affects the body's immune system by targeting a specific type of white blood cell that plays a crucial role in resisting infections. Various treatments, including antibiotics and antivirals, are available, with testing conducted in diverse settings such as laboratory testing and point-of-care (POC) testing. These treatments are administered via oral, parenteral, and other routes and are commonly provided in hospitals, specialty clinics, homecare, and other healthcare settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The sexually transmitted infections (STIs) market research report is one of a series of new reports from The Business Research Company that provides sexually transmitted infections (STIs) market statistics, including sexually transmitted infections (STIs) industry global market size, regional shares, competitors with a sexually transmitted infections (STIs) market share, detailed sexually transmitted infections (STIs) market segments, market trends and opportunities and any further data you may need to thrive in the sexually transmitted infections (STIs) industry. This sexually transmitted infections (STIs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sexually transmitted infections (stis) market size has grown rapidly in recent years. It will grow from $63.69 billion in 2024 to $71.28 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to behavioral factors, education and awareness, healthcare access, antibiotic development.

The sexually transmitted infections (stis) market size is expected to see rapid growth in the next few years. It will grow to $112.02 billion in 2029 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to emerging sti strains, vaccination initiatives, telemedicine and at-home testing, sexual health equity. Major trends in the forecast period include rise of antimicrobial resistance, pre-exposure prophylaxis (prep), sti self-management, enhanced sexual education.

The forecast of 12.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of multiplex Polymerase Chain Reaction Sexually Transmitted Infection panels and rapid syphilis tests sourced from Belgium and China, thereby delaying diagnosis and elevating public health screening program costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Government-driven initiatives are playing a pivotal role in fueling the growth of the sexually transmitted infections (STIs) market. These government initiatives encompass a range of programs and policies aimed at raising awareness of STIs and are expected to be a driving force behind the market's expansion. These programs are specifically designed to address the challenges associated with STIs and typically involve allocating funds for public education campaigns to increase STI awareness. Additionally, government initiatives may include the development of vaccines to prevent certain STIs and the provision of free or low-cost screening and testing services. A notable example is the Disease Intervention Specialist (DIS) program launched by the Springfield-Greene County Health department in April 2023, in collaboration with the Missouri Department of Health and Senior Services (Missouri DHSS). This program focuses on countering the increasing prevalence of sexually transmitted infections, with a primary emphasis on syphilis and HIV. The DIS program involves experts who proactively reach out to individuals who have tested positive for these infections, facilitating access to treatment and ensuring contact tracing to raise awareness about potential infection. Therefore, government initiatives are expected to be a driving factor for the growth of the sexually transmitted infections (STIs) market.

The growing prevalence of unprotected sex is expected to drive the growth of the sexually transmitted infections (STIs) market. The increasing practice of unprotected sex refers to engaging in sexual activities without using protection, such as condoms, which can lead to the spread of sexually transmitted infections. For example, in August 2024, the World Health Organization reported that in 2022, the percentage of sexually active adolescents using condoms during their most recent intercourse decreased, with 61% of boys and 57% of girls reporting condom use, down from 70% and 63%, respectively. Thus, the rise in unprotected sex is contributing to the expansion of the STIs market.

Major companies within the sexually transmitted infections (STIs) market are pioneering innovative products that incorporate fluorescent PCR technology to gain a competitive edge in the market. Fluorescent PCR (Polymerase Chain Reaction) technology is a molecular biology technique used to detect and quantify specific DNA sequences in a biological sample. For instance, in March 2023, Jiangsu Bioperfectus Technologies Co. Ltd., a China-based provider of molecular diagnostic solutions, introduced two new polymerase chain reaction (PCR) kits including the Mycoplasma Hominis Real-Time PCR Kit and the Treponema Pallidum Real-Time PCR Kit. These kits offer a comprehensive PCR solution for the early diagnosis of sexually transmitted infections, which affect a significant population. The BioPerfectus Mycoplasma Hominis Real-Time PCR Kit is a reagent that utilizes fluorescent PCR technology to detect Mycoplasma hominis in human male urethral swabs, female cervical or vaginal swabs, and urine samples. The BioPerfectus Treponema Pallidum Real-Time PCR Kit is designed to detect treponema pallidum nucleic acid in human serum and plasma.

In February 2023, Caraway Health, a US-based provider of digital healthcare services for Generation Z, entered into a partnership with Ash Wellness Inc. The collaboration addresses the surge in sexually transmitted infections (STIs) on university campuses among Generation Z. This partnership equips Generation Z with the tools necessary to prioritize their sexual well-being on their own terms. Ash Wellness Inc. is a US-based provider of remote diagnostic solutions, including home HIV and STI testing.

Major companies operating in the sexually transmitted infections (stis) market are Pfizer Inc., Johnson & Johnson, Roche Holdings AG, Merck & Co Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories, Wockhardt Ltd., Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd.

North America was the largest region in the sexually transmitted infection (STIs) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sexually transmitted infections (STIs) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sexually transmitted infections (STIs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sexually transmitted infections (STIs) market consists of revenues earned by entities by providing services such as treatment, testing, awareness programs and diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The sexually transmitted infections (STIs) market also includes the sales of treatments such as testing kits, vaccines and medication. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sexually Transmitted Infections (STIs) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sexually transmitted infections (stis) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sexually transmitted infections (stis) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sexually transmitted infections (stis) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Human Immunodeficiency Virus (HIV); Human Papilloma Virus (HPV); Gonorrhea; Syphilis; Other Types
  • 2) By Treatment: Antibiotics; Antiviral
  • 3) By Location Of Testing: Laboratory Testing; Point-Of-Care (POC) Testing
  • 4) By Route Of Administration: Oral; Parenteral; Other Route Of Administration
  • 5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
  • Subsegments:
  • 1) By Human Immunodeficiency Virus (HIV): HIV Type 1; HIV Type 2
  • 2) By Human Papilloma Virus (HPV): Low-Risk HPV; High-Risk HPV
  • 3) By Gonorrhea: Uncomplicated Gonorrhea; Complicated Gonorrhea
  • 4) By Syphilis: Primary Syphilis; Secondary Syphilis; Tertiary Syphilis
  • 5) By Other Types: Chlamydia; Herpes Simplex Virus (HSV); Hepatitis B; Hepatitis C; Trichomoniasis
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holdings AG; Merck & Co Inc.; AbbVie Inc.; Novartis AG; Sanofi SA; Bristol-Myers Squibb; Astra Zeneca Pharmaceuticals LP; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Gilead Sciences Inc.; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Astellas Pharma Inc.; Daiichi Sankyo Co. Ltd.; Hetero Drugs Ltd.; Eisai Co. Ltd.; Boehringer Ingelheim Group; Sun Pharmaceutical Industries Ltd.; Lupin Limited; Dr. Reddy's Laboratories; Wockhardt Ltd.; Zydus Lifescience Ltd.; Glenmark Pharmaceuticals Ltd.; Cipla Ltd.; Torrent Pharmaceuticals Ltd.; Otsuka Pharmaceutical Co. Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Sexually Transmitted Infections (STIs) Market Characteristics

3. Sexually Transmitted Infections (STIs) Market Trends And Strategies

4. Sexually Transmitted Infections (STIs) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Sexually Transmitted Infections (STIs) Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Sexually Transmitted Infections (STIs) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Sexually Transmitted Infections (STIs) Market Growth Rate Analysis
  • 5.4. Global Sexually Transmitted Infections (STIs) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Sexually Transmitted Infections (STIs) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Sexually Transmitted Infections (STIs) Total Addressable Market (TAM)

6. Sexually Transmitted Infections (STIs) Market Segmentation

  • 6.1. Global Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Human Immunodeficiency Virus (HIV)
  • Human Papilloma Virus (HPV)
  • Gonorrhea
  • Syphilis
  • Other Types
  • 6.2. Global Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antibiotics
  • Antiviral
  • 6.3. Global Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Laboratory Testing
  • Point-Of-Care (POC) Testing
  • 6.4. Global Sexually Transmitted Infections (STIs) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Parenteral
  • Other Route Of Administration
  • 6.5. Global Sexually Transmitted Infections (STIs) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Other End-Users
  • 6.6. Global Sexually Transmitted Infections (STIs) Market, Sub-Segmentation Of Human Immunodeficiency Virus (HIV), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • HIV Type 1
  • HIV Type 2
  • 6.7. Global Sexually Transmitted Infections (STIs) Market, Sub-Segmentation Of Human Papilloma Virus (HPV), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Low-Risk HPV
  • High-Risk HPV
  • 6.8. Global Sexually Transmitted Infections (STIs) Market, Sub-Segmentation Of Gonorrhea, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Uncomplicated Gonorrhea
  • Complicated Gonorrhea
  • 6.9. Global Sexually Transmitted Infections (STIs) Market, Sub-Segmentation Of Syphilis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Primary Syphilis
  • Secondary Syphilis
  • Tertiary Syphilis
  • 6.10. Global Sexually Transmitted Infections (STIs) Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Chlamydia
  • Herpes Simplex Virus (HSV)
  • Hepatitis B
  • Hepatitis C
  • Trichomoniasis

7. Sexually Transmitted Infections (STIs) Market Regional And Country Analysis

  • 7.1. Global Sexually Transmitted Infections (STIs) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Sexually Transmitted Infections (STIs) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Sexually Transmitted Infections (STIs) Market

  • 8.1. Asia-Pacific Sexually Transmitted Infections (STIs) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Sexually Transmitted Infections (STIs) Market

  • 9.1. China Sexually Transmitted Infections (STIs) Market Overview
  • 9.2. China Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Sexually Transmitted Infections (STIs) Market

  • 10.1. India Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Sexually Transmitted Infections (STIs) Market

  • 11.1. Japan Sexually Transmitted Infections (STIs) Market Overview
  • 11.2. Japan Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Sexually Transmitted Infections (STIs) Market

  • 12.1. Australia Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Sexually Transmitted Infections (STIs) Market

  • 13.1. Indonesia Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Sexually Transmitted Infections (STIs) Market

  • 14.1. South Korea Sexually Transmitted Infections (STIs) Market Overview
  • 14.2. South Korea Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Sexually Transmitted Infections (STIs) Market

  • 15.1. Western Europe Sexually Transmitted Infections (STIs) Market Overview
  • 15.2. Western Europe Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Sexually Transmitted Infections (STIs) Market

  • 16.1. UK Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Sexually Transmitted Infections (STIs) Market

  • 17.1. Germany Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Sexually Transmitted Infections (STIs) Market

  • 18.1. France Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Sexually Transmitted Infections (STIs) Market

  • 19.1. Italy Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Sexually Transmitted Infections (STIs) Market

  • 20.1. Spain Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Sexually Transmitted Infections (STIs) Market

  • 21.1. Eastern Europe Sexually Transmitted Infections (STIs) Market Overview
  • 21.2. Eastern Europe Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Sexually Transmitted Infections (STIs) Market

  • 22.1. Russia Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Sexually Transmitted Infections (STIs) Market

  • 23.1. North America Sexually Transmitted Infections (STIs) Market Overview
  • 23.2. North America Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Sexually Transmitted Infections (STIs) Market

  • 24.1. USA Sexually Transmitted Infections (STIs) Market Overview
  • 24.2. USA Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Sexually Transmitted Infections (STIs) Market

  • 25.1. Canada Sexually Transmitted Infections (STIs) Market Overview
  • 25.2. Canada Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Sexually Transmitted Infections (STIs) Market

  • 26.1. South America Sexually Transmitted Infections (STIs) Market Overview
  • 26.2. South America Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Sexually Transmitted Infections (STIs) Market

  • 27.1. Brazil Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Sexually Transmitted Infections (STIs) Market

  • 28.1. Middle East Sexually Transmitted Infections (STIs) Market Overview
  • 28.2. Middle East Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Sexually Transmitted Infections (STIs) Market

  • 29.1. Africa Sexually Transmitted Infections (STIs) Market Overview
  • 29.2. Africa Sexually Transmitted Infections (STIs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Sexually Transmitted Infections (STIs) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Sexually Transmitted Infections (STIs) Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Sexually Transmitted Infections (STIs) Market Competitive Landscape And Company Profiles

  • 30.1. Sexually Transmitted Infections (STIs) Market Competitive Landscape
  • 30.2. Sexually Transmitted Infections (STIs) Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Roche Holdings AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Sexually Transmitted Infections (STIs) Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Sanofi SA
  • 31.3. Bristol-Myers Squibb
  • 31.4. Astra Zeneca Pharmaceuticals LP
  • 31.5. GlaxoSmithKline plc
  • 31.6. Takeda Pharmaceutical Company Limited
  • 31.7. Gilead Sciences Inc.
  • 31.8. Viatris Inc.
  • 31.9. Teva Pharmaceutical Industries Ltd.
  • 31.10. Astellas Pharma Inc.
  • 31.11. Daiichi Sankyo Co. Ltd.
  • 31.12. Hetero Drugs Ltd.
  • 31.13. Eisai Co. Ltd.
  • 31.14. Boehringer Ingelheim Group
  • 31.15. Sun Pharmaceutical Industries Ltd.

32. Global Sexually Transmitted Infections (STIs) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sexually Transmitted Infections (STIs) Market

34. Recent Developments In The Sexually Transmitted Infections (STIs) Market

35. Sexually Transmitted Infections (STIs) Market High Potential Countries, Segments and Strategies

  • 35.1 Sexually Transmitted Infections (STIs) Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Sexually Transmitted Infections (STIs) Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Sexually Transmitted Infections (STIs) Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제